Drug intelligence / Profile preview

QR057

Development stage: Preclinical
Lead developer: Wuhan Createrna Science and Technology
Modality: Small Molecules

Overview

QR057 is an investigational small molecule drug candidate currently being developed by Createrna Development for the treatment of cough. As of the latest pipeline updates, the asset is in the IND-enabling (preclinical) stage of development. While Createrna Development has other respiratory assets with disclosed mechanisms, such as the P2X3 antagonist QR059, the specific molecular target and mechanism of action for QR057 have not yet been publicly characterized. The drug is part of the company's internal research program focusing on respiratory and inflammatory diseases.

Beyond the preview

Go deeper on QR057.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QR057.

Explore the full profile